​

RxSight (RXST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RXST Stock Forecast

RxSight (RXST) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $8.83, with a high of $11.00 and a low of $6.50. This represents a 70.13% increase from the last price of $5.19.

$5 $17 $29 $41 $53 $65 High: $11 Avg: $8.83 Low: $6.5 Last Closed Price: $5.19

RXST Stock Rating

RxSight stock's rating consensus is Hold, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (25.00%), 7 Hold (58.33%), 2 Sell (16.67%), and 0 Strong Sell (0.00%).

Hold
Total 12 0 2 7 3 Strong Sell Sell Hold Buy Strong Buy

RXST Price Target Upside V Benchmarks

TypeNameUpside
StockRxSight70.13%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks30.52%

Price Target Trends

1M3M12M
# Anlaysts127
Avg Price Target$6.50$8.75$10.07
Last Closing Price$5.19$5.19$5.19
Upside/Downside25.24%68.59%94.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 261-6-29
Jun, 261-6-29
May, 261-6-29
Apr, 261-6-29
Mar, 261-8-211
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 07, 2026Jefferies$6.50$5.6215.66%25.24%
May 07, 2026Needham$11.00$6.0382.42%111.95%
Mar 09, 2026Thomas StephanStifel Nicolaus$9.00$7.5718.89%73.41%
Feb 26, 2026David SaxonNeedham$13.00$8.8147.56%150.48%
Jan 20, 2026Piper Sandler$11.00$9.8112.13%111.95%
Dec 02, 2025Morgan Stanley$10.00$11.65-14.16%92.68%
Nov 06, 2025Stifel Nicolaus$10.00$8.7314.55%92.68%
Oct 29, 2024Curry BakerGuggenheim$52.00$52.00-901.93%
Oct 29, 2024Anthony CrowdellMizuho Securities$67.00$52.0028.85%1190.94%
Oct 29, 2024Adam SeidenBarclays$110.00$52.00111.54%2019.46%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 26, 2026NeedhamBuyBuyhold
Jan 30, 2026William BlairMarket Performinitialise
Jan 30, 2026Wolfe ResearchOutperformupgrade
Jan 20, 2026Piper SandlerNeutralNeutralhold
Jan 12, 2026UBSNeutralNeutralhold
Jul 10, 2025JefferiesBuyHolddowngrade
May 19, 2025Wells FargoBuyOverweightupgrade
Apr 15, 2025Piper SandlerNeutralinitialise
Oct 29, 2024BarclaysOverweightinitialise
Oct 29, 2024Wells FargoBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.78$-2.41$-1.41$-0.71$-0.95---
Avg Forecast$-2.66$-2.61$-1.53$-0.72$-0.45$-0.05$-0.08$-0.14
High Forecast$-2.51$-2.50$-1.48$5.06$-0.13$0.03$-0.07$-0.14
Low Forecast$-2.79$-2.78$-1.56$-5.06$-0.90$-0.12$-0.08$-0.14
Surprise %-33.08%-7.66%-7.84%-1.39%111.11%---

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.59M$49.01M$89.08M$139.93M$134.48M---
Avg Forecast$22.04M$48.76M$88.44M$140.03M$188.50M$231.79M$284.80M$300.70M
High Forecast$22.84M$51.18M$89.27M$140.10M$189.45M$232.46M$295.90M$303.50M
Low Forecast$21.04M$47.21M$86.59M$139.97M$187.66M$231.11M$273.70M$294.39M
Surprise %2.53%0.50%0.72%-0.07%-28.66%---

Net Income Forecast

$-200M $-120M $-40M $40M $120M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-48.69M$-66.76M$-48.61M$-27.45M$-38.94M---
Avg Forecast$-91.76M$-89.86M$-52.40M$-30.69M$-17.24M$-1.03M$-2.56M$-4.82M
High Forecast$-86.38M$-86.15M$-51.02M$174.36M$-4.59M$973.35K$-2.51M$-4.69M
Low Forecast$-96.13M$-95.64M$-53.78M$-174.36M$-30.96M$-4.14M$-2.62M$-4.88M
Surprise %-46.94%-25.71%-7.24%-10.55%125.88%---

RXST Forecast FAQ

Is RxSight stock a buy?

RxSight stock has a consensus rating of Hold, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 7 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that RxSight is a neutral investment for most analysts.

What is RxSight's price target?

RxSight's price target, set by 12 Wall Street analysts, averages $8.83 over the next 12 months. The price target range spans from $6.5 at the low end to $11 at the high end, suggesting a potential 70.13% change from the previous closing price of $5.19.

How does RxSight stock forecast compare to its benchmarks?

RxSight's stock forecast shows a 70.13% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (30.52%).

What is the breakdown of analyst ratings for RxSight over the past three months?

  • July 2026: 11.11% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 22.22% Strong Sell.
  • June 2026: 11.11% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 22.22% Strong Sell.
  • May 2026: 11.11% Strong Buy, 0% Buy, 66.67% Hold, 0% Sell, 22.22% Strong Sell.

What is RxSight’s EPS forecast?

RxSight's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.05, marking a -94.74% decrease from the reported $-0.95 in 2025. Estimates for the following years are $-0.08 in 2027, and $-0.14 in 2028.

What is RxSight’s revenue forecast?

RxSight's average annual revenue forecast for its fiscal year ending in December 2026 is $231.79M, reflecting a 72.36% increase from the reported $134.48M in 2025. The forecast for 2027 is $284.8M, and $300.7M for 2028.

What is RxSight’s net income forecast?

RxSight's net income forecast for the fiscal year ending in December 2026 stands at $-1.029M, representing a -97.36% decrease from the reported $-38.943M in 2025. Projections indicate $-2.564M in 2027, and $-4.824M in 2028.